Publications

• Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.
  Blood Cancer J Volume: 15 Page(s): 55
  04/03/2025 Authors: Hoff FW; Huang Y; Welkie RL; Swords RT; Traer E; Stein EM; Lin TL; Patel PA; Collins RH; Baer MR
• Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies.
  Leukemia Volume: 39 Page(s): 623 - 631
  03/01/2025 Authors: Anabtawi N; Nicolet D; Alotaibi N; Buelow DR; Orwick S; Gregory T; Raj R; Coleman K; Kolitz JE; Powell BL
• Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.
  J Hematol Oncol Volume: 18 Page(s): 7
  01/16/2025 Authors: Cortes JE; Roboz GJ; Baer MR; Jonas BA; Schiller GJ; Yee K; Ferrell PB; Yang J; Wang ES; Blum WG
• Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
  Blood Adv Volume: 8 Page(s): 5297 - 5305
  10/22/2024 Authors: Hoff FW; Blum WG; Huang Y; Welkie RL; Swords RT; Traer E; Stein EM; Lin TL; Archer KJ; Patel PA
• A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
  Blood Adv Volume: 8 Page(s): 429 - 440
  01/23/2024 Authors: Cai SF; Huang Y; Lance JR; Mao HC; Dunbar AJ; McNulty SN; Druley T; Li Y; Baer MR; Stock W
• Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG).
  Leukemia Volume: 38 Page(s): 45 - 57
  01/01/2024 Authors: Ozga M; Nicolet D; Mrzek K; Yilmaz AS; Kohlschmidt J; Larkin KT; Blachly JS; Oakes CC; Buss J; Walker CJ
• Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
  Leuk Lymphoma Volume: 64 Page(s): 2091 - 2100
  12/01/2023 Authors: Bhatnagar B; Zhao Q; Mims AS; Vasu S; Behbehani GK; Larkin K; Blachly JS; Badawi MA; Hill KL; Dzwigalski KR
• Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratories.
  Blood Adv Volume: 7 Page(s): 6048 - 6054
  10/24/2023 Authors: Borate U; Yang F; Press R; Ruppert AS; Jones D; Caruthers S; Zhao W; Vergilio J-A; Pavlick DC; Juckett L
• Association of social deprivation with survival in younger adult patients with AML: an Alliance study.
  Blood Adv Volume: 7 Page(s): 4019 - 4023
  08/08/2023 Authors: Rebechi M; Kohlschmidt J; Mrzek K; Nicolet D; Mims AS; Blachly JS; Orwick S; Larkin KT; Oakes CC; Hantel A
• Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
  Cancer Volume: 129 Page(s): 2308 - 2320
  08/01/2023 Authors: Duong VH; Ruppert AS; Mims AS; Borate U; Stein EM; Baer MR; Stock W; Kovacsovics T; Blum W; Arellano ML
• Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
  Blood Adv Volume: 7 Page(s): 3117 - 3127
  07/11/2023 Authors: de Botton S; Fenaux P; Yee K; Rcher C; Wei AH; Montesinos P; Taussig DC; Pigneux A; Braun T; Curti A
• Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
  Blood Adv Volume: 7 Page(s): 2360 - 2363
  06/13/2023 Authors: Saliba AN; Kaufmann SH; Stein EM; Patel PA; Baer MR; Stock W; Deininger M; Blum W; Schiller GJ; Olin RL
• BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
  J Immunother Cancer Volume: 11
  05/01/2023 Authors: Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S
• Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.
  Leukemia Volume: 37 Page(s): 788 - 798
  04/01/2023 Authors: Mrzek K; Kohlschmidt J; Blachly JS; Nicolet D; Carroll AJ; Archer KJ; Mims AS; Larkin KT; Orwick S; Oakes CC
• North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
  Blood Volume: 141 Page(s): 567 - 578
  02/09/2023 Authors: Pemmaraju N; Kantarjian H; Sweet K; Wang E; Senapati J; Wilson NR; Konopleva M; Frankel AE; Gupta V; Mesa R
• An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia.
  Haematologica Volume: 107 Page(s): 2977 - 2982
  12/01/2022 Authors: Fiedler W; Montesinos P; Schliemann C; Middeke J; Vasu S; Scholz CW; Esteve J; Mondal S; Rter B; Burkard U
• High early death rates, treatment resistance, and short survival ofBlack adolescents and young adults with AML.
  Blood Adv Volume: 6 Page(s): 5570 - 5581
  10/11/2022 Authors: Larkin KT; Nicolet D; Kelly BJ; Mrzek K; LaHaye S; Miller KE; Wijeratne S; Wheeler G; Kohlschmidt J; Blachly JS
• A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia.
  Haematologica Volume: 107 Page(s): 770 - 773
  03/01/2022 Authors: Vasu S; Altman JK; Uy GL; Tallman MS; Gojo I; Lozanski G; Burkard U; Osswald A; James P; Rter B
• Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
  Mol Cell Volume: 81 Page(s): 3833 - 3847.e11
  09/16/2021 Authors: Chen D; Xia S; Zhang R; Li Y; Famulare CA; Fan H; Wu R; Wang M; Zhu AC; Elf SE
• Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial.
  Ther Innov Regul Sci Volume: 55 Page(s): 926 - 935
  09/01/2021 Authors: Rosenberg L; Levaux H; Levine RL; Shah A; Denmark J; Hereema N; Owen M; Kalk S; Kenny N; Vinson G
• Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).
  Blood Adv Volume: 5 Page(s): 2775 - 2787
  07/13/2021 Authors: Walker AR; Marcucci G; Yin J; Blum W; Stock W; Kohlschmidt J; Mrzek K; Carroll AJ; Eisfeld A-K; Wang ES
• A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
  Am J Hematol Volume: 95 Page(s): 1457 - 1465
  12/01/2020 Authors: Saygin C; Larkin K; Blachly JS; Orwick S; Ngankeu A; Gregory CT; Phelps MA; Mani S; Walker A; Garzon R
• Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
  Nat Med Volume: 26 Page(s): 1852 - 1858
  12/01/2020 Authors: Burd A; Levine RL; Ruppert AS; Mims AS; Borate U; Stein EM; Patel P; Baer MR; Stock W; Deininger M
• Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression.
  Clin Cancer Res Volume: 26 Page(s): 5852 - 5859
  11/15/2020 Authors: Walker AR; Byrd JC; Blachly JS; Bhatnagar B; Mims AS; Orwick S; Lin TL; Crosswell HE; Zhang D; Minden MD
• Treating acute myeloid leukemia in the modern era: A primer.
  Cancer Volume: 126 Page(s): 4668 - 4677
  11/01/2020 Authors: Blum WG; Mims AS
• Phase I study of AR-42 and decitabine in acute myeloid leukemia.
  Leuk Lymphoma Volume: 61 Page(s): 1484 - 1492
  06/01/2020 Authors: Liva SG; Coss CC; Wang J; Blum W; Klisovic R; Bhatnagar B; Walsh K; Geyer S; Zhao Q; Garzon R
• Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
  Invest New Drugs Volume: 38 Page(s): 340 - 349
  04/01/2020 Authors: Jeon JY; Zhao Q; Buelow DR; Phelps M; Walker AR; Mims AS; Vasu S; Behbehani G; Blachly J; Blum W
• Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
  Blood Adv Volume: 4 Page(s): 696 - 705
  02/25/2020 Authors: Marcucci G; Geyer S; Laumann K; Zhao W; Bucci D; Uy GL; Blum W; Eisfeld A-K; Pardee TS; Wang ES
• Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study.
  Leuk Lymphoma Volume: 61 Page(s): 387 - 396
  02/01/2020 Authors: Bhatnagar B; Zhao Q; Mims AS; Vasu S; Behbehani GK; Larkin K; Blachly JS; Blum W; Klisovic RB; Ruppert AS
• Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.
  Leukemia Volume: 33 Page(s): 1620 - 1634
  07/01/2019 Authors: Mrzek K; Eisfeld A-K; Kohlschmidt J; Carroll AJ; Walker CJ; Nicolet D; Blachly JS; Bill M; Papaioannou D; Wang ES
• Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614).
  Blood Adv Volume: 3 Page(s): 1714 - 1721
  06/11/2019 Authors: Yin J; LaPlant B; Uy GL; Marcucci G; Blum W; Larson RA; Stone RM; Mandrekar SJ
• Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?
  Bone Marrow Transplant Volume: 54 Page(s): 913 - 916
  06/01/2019 Authors: Vaughn JL; Zhao Q; Epperla N; Puto M; Roddy J; Elder P; Blum W; Klisovic R; Jaglowski S; Penza S
• Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
  Cancer Discov Volume: 9 Page(s): 756 - 777
  06/01/2019 Authors: Chen D; Xia S; Wang M; Lin R; Li Y; Mao H; Aguiar M; Famulare CA; Shih AH; Brennan CW
• Population pharmacokinetics of lenalidomide in patients with B-cell malignancies.
  Br J Clin Pharmacol Volume: 85 Page(s): 924 - 934
  05/01/2019 Authors: Hughes JH; Phelps MA; Upton RN; Reuter SE; Gao Y; Byrd JC; Grever MR; Hofmeister CC; Marcucci G; Blum W
• Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
  N Engl J Med Volume: 380 Page(s): 1628 - 1637
  04/25/2019 Authors: Pemmaraju N; Lane AA; Sweet KL; Stein AS; Vasu S; Blum W; Rizzieri DA; Wang ES; Duvic M; Sloan JM
• Progress in the problem of relapsed or refractory acute myeloid leukemia.
  Curr Opin Hematol Volume: 26 Page(s): 88 - 95
  03/01/2019 Authors: Mims AS; Blum W
• PHARMACOKINETICS OF SELINEXOR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A PHASE I TRIAL.
  Volume: 105 Page(s): S51 - S51
  03/01/2019 Authors: Badawi M; Walker A; Mims A; Vasu S; Blum W; Klisovic R; Bhatnagar B; Phelps M
• Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
  Volume: 132
  11/29/2018 Authors: Pemmaraju N; Lane AA; Sweet KL; Stein AS; Vasu S; Blum W; Rizzieri DA; Wang ES; Duvic M; Spence S
• Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial
  Volume: 132
  11/29/2018 Authors: Stein EM; Shoben A; Borate U; Baer MR; Stock W; Patel PA; Kovacsovics T; Blum W; Vergilio J-A; Heerema NA
• Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients.
  Bone Marrow Transplant Volume: 53 Page(s): 1418 - 1427
  11/01/2018 Authors: Richardson DR; Huang Y; McGinty HL; Elder P; Newlin J; Kirkendall C; Andritsos L; Benson D; Blum W; Efebera Y
• The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.
  Haematologica Volume: 103 Page(s): 1288 - 1297
  08/01/2018 Authors: Mani R; Goswami S; Gopalakrishnan B; Ramaswamy R; Wasmuth R; Tran M; Mo X; Gordon A; Bucci D; Lucas DM
• High response rates with entospletinib in patients with t(v; 11q23.3); KMT2Arearranged acute myeloid leukemia and acute lymphoblastic leukemia
  Volume: 78
  07/01/2018 Authors: Walker AR; Byrd JC; Blum W; Lin T; Crosswell HE; Zhang D; Gao J; Rao AV; Minden MD; Stock W
• A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.
  Haematologica Volume: 103 Page(s): 982 - 987
  06/01/2018 Authors: Mims AS; Mishra A; Orwick S; Blachly J; Klisovic RB; Garzon R; Walker AR; Devine SM; Walsh KJ; Vasu S
• Phase 1 study of selinexor plus mitoxantrone, etoposide, and cytarabine in acute myeloid leukemia.
  Volume: 36
  05/20/2018 Authors: Bhatnagar B; Walker AR; Mims AS; Vasu S; Klisovic RB; Behbehani G; Blachly JS; Larkin KTM; Long M; Zhao Q
• Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.
  Oncotarget Volume: 9 Page(s): 9706 - 9713
  02/09/2018 Authors: Gopalakrishnan B; Cheney C; Mani R; Mo X; Bucci D; Walker A; Klisovic R; Bhatnagar B; Walsh K; Rueter B
• Response Rates, Non-Relapse Mortality, and Financial Implications of Transplant-Associated Thrombotic Microangiopathy Treated with Eculizumab
  Volume: 130
  12/07/2017 Authors: Vaughn JL; Zhao Q; Ranganathan P; Elder P; William BM; Puto M; Roddy J; Klisovic R; Blum W; Benson DM
• Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity
  Volume: 130
  12/07/2017 Authors: Wall SA; Zhao Q; Ranganathan P; Elder P; William BM; Puto M; Roddy J; Klisovic RB; Blum W; Benson DM
• Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
  Cancer Volume: 123 Page(s): 3061 - 3072
  08/15/2017 Authors: Khoury HJ; Collins RH; Blum W; Stiff PS; Elias L; Lebkowski JS; Reddy A; Nishimoto KP; Sen D; Wirth ED
• Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia.
  Haematologica Volume: 102 Page(s): 1391 - 1400
  08/01/2017 Authors: Papaioannou D; Nicolet D; Volinia S; Mrzek K; Yan P; Bundschuh R; Carroll AJ; Kohlschmidt J; Blum W; Powell BL
• Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
  J Natl Compr Canc Netw Volume: 15 Page(s): 926 - 957
  07/01/2017 Authors: O'Donnell MR; Tallman MS; Abboud CN; Altman JK; Appelbaum FR; Arber DA; Bhatt V; Bixby D; Blum W; Coutre SE
• INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML
  Volume: 102 Page(s): 217 - 218
  06/26/2017 Authors: Cortes J; DeAngelo D; Wang E; Arana-Yi C; Zweidler-McKay P; Munteanu M; Andreu-Vieyra C; Erba H; Blum W; Traer E
• ONGOING PHASE 2 CLINICAL TRIAL OF SL-401 IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM: STAGE 1 AND STAGE 2 RESULTS
  Volume: 102 Page(s): 43 - 43
  06/26/2017 Authors: Pemmaraju N; Sweet K; Lane A; Stein A; Vasu S; Blum W; Rizzieri D; Wang E; Duvic M; Chen J
• OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.
  Cancer Res Volume: 77 Page(s): 2102 - 2111
  04/15/2017 Authors: Drenberg CD; Gibson AA; Pounds SB; Shi L; Rhinehart DP; Li L; Hu S; Du G; Nies AT; Schwab M
• Making the most of hypomethylating agents in myelodysplastic syndrome.
  Curr Opin Hematol Volume: 24 Page(s): 79 - 88
  03/01/2017 Authors: Bhatt G; Blum W
• E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemia.
  Leukemia Volume: 31 Page(s): 502 - 505
  02/01/2017 Authors: Park I-K; Blum W; Baker SD; Caligiuri MA
• A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.
  Blood Adv Volume: 1 Page(s): 331 - 340
  01/24/2017 Authors: Uy GL; Mandrekar SJ; Laumann K; Marcucci G; Zhao W; Levis MJ; Klepin HD; Baer MR; Powell BL; Westervelt P
• Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503).
  Leukemia Volume: 31 Page(s): 34 - 39
  01/01/2017 Authors: Blum W; Sanford BL; Klisovic R; DeAngelo DJ; Uy G; Powell BL; Stock W; Baer MR; Kolitz JE; Wang ES
• XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II to the Nucleus.
  Clin Cancer Res Volume: 22 Page(s): 6142 - 6152
  12/15/2016 Authors: Ranganathan P; Kashyap T; Yu X; Meng X; Lai T-H; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM
• Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts
  Volume: 128
  12/02/2016 Authors: Richardson DR; Zhao Q; Kitzler R; Elder P; Lozanski G; Andritsos LA; Benson DM; Blum W; Efebera YA; Jaglowski S
• Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation
  Volume: 128
  12/02/2016 Authors: Auletta JJ; Ardura MI; Vasu S; Huang Y; Zhao Q; Ruppert AS; Shoben A; Elder P; Bingman A; Kitzler R
• Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia
  Volume: 128
  12/02/2016 Authors: Yin J; Laplant BR; Uy GL; Marcucci G; Blum W; Larson RA; Stone RM; Mandrekar S
• SL-401 Mediates Potent Cytotoxicity Against CD123+AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model
  Volume: 128
  12/02/2016 Authors: Mani R; Goswami S; Gopalakrishnan B; Ramaswamy R; Wasmuth R; Tran M; Mo X; Gordon A; Bucci D; Lucas D
• MicroRNA-29b mediates altered innate immune development in acute leukemia.
  J Clin Invest Volume: 126 Page(s): 4404 - 4416
  12/01/2016 Authors: Mundy-Bosse BL; Scoville SD; Chen L; McConnell K; Mao HC; Ahmed EH; Zorko N; Harvey S; Cole J; Zhang X
• Why the stagnation in effective therapy for MDS?
  Best Pract Res Clin Haematol Volume: 29 Page(s): 334 - 340
  12/01/2016 Authors: Blum W
• Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
  Br J Haematol Volume: 175 Page(s): 226 - 236
  10/01/2016 Authors: Bhatnagar B; Eisfeld A-K; Nicolet D; Mrzek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE
• Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
  Cancer Discov Volume: 6 Page(s): 1106 - 1117
  10/01/2016 Authors: Konopleva M; Pollyea DA; Potluri J; Chyla B; Hogdal L; Busman T; McKeegan E; Salem AH; Zhu M; Ricker JL
• Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.
  Bone Marrow Transplant Volume: 51 Page(s): 1241 - 1244
  09/01/2016 Authors: Vasu S; Wu H; Satoskar A; Puto M; Roddy J; Blum W; Klisovic R; Andritsos L; Hofmeister C; Benson DM
• Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
  Leuk Lymphoma Volume: 57 Page(s): 2100 - 2108
  09/01/2016 Authors: Walker AR; Wang H; Walsh K; Bhatnagar B; Vasu S; Garzon R; Canning R; Geyer S; Wu Y-Z; Devine SM
• Decitabine response in FLT3-negative AML is associated with mitochondrial priming
  Volume: 76
  07/01/2016 Authors: Dettman E; Doykan C; Ishizawa J; Zhang W; Walker A; Blum W; Klisovic R; Cardone M; Andreeff M; Johnson A
• Erratum to "Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease" [Biol Blood Marrow Transplant 22(2016):658-668].
  Biol Blood Marrow Transplant Volume: 22 Page(s): 1341
  07/01/2016 Authors: Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L
• Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts.
  Blood Volume: 127 Page(s): 2879 - 2889
  06/09/2016 Authors: Vasu S; He S; Cheney C; Gopalakrishnan B; Mani R; Lozanski G; Mo X; Groh V; Whitman SP; Konopitzky R
• A TWO-CENTER RETROSPECTIVE COMPARISON OF BEAM VS BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA
  Volume: 101 Page(s): 625 - 626
  06/01/2016 Authors: Singer S; Efebera YA; Zhao Q; Abounader D; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos L; Klisovic R
• A TWO-CENTER RETROSPECTIVE COMPARISON OF BEAM VS BUCYVP16 CONDITIONING PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HODGKIN'S LYMPHOMA
  Volume: 101 Page(s): 625 - 625
  06/01/2016 Authors: Singer S; Efebera YA; Zhao Q; Abounader D; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos L; Klisovic R
• RESULTS FROM ONGOING PHASE 2 REGISTRATION STUDY OF SL-401 IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
  Volume: 101 Page(s): 327 - 327
  06/01/2016 Authors: Pemmaraju N; Lane A; Sweet K; Stein A; Vasu S; Blum W; Rizzieri D; Wang E; Duvic M; Chen J
• LONG NON-CODING RNA PROFILING PROVIDES IMPORTANT PROGNOSTIC INFORMATION AND BIOLOGIC INSIGHTS IN YOUNGER PATIENTS WITH CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA (ALLIANCE/CALGB 8461, 9665, 20202)
  Volume: 101 Page(s): 326 - 326
  06/01/2016 Authors: Papaioannou D; Nicolet D; Volinia S; Mrozek K; Yan P; Carroll AJ; Kohlschmidt J; Blum W; Powell BL; Uy GL
• Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing.
  Volume: 34
  05/20/2016 Authors: Pemmaraju N; Lane AA; Sweet KL; Stein AS; Vasu S; Blum WG; Rizzieri D; Wang ES; Duvic M; Chen J
• Long-Term Relapse-Free Survival of Patients with Acute Myeloid Leukemia (AML) Receiving a Telomerase-Engineered Dendritic Cell Immunotherapy
  Volume: 24 Page(s): S110 - S110
  05/01/2016 Authors: Lebkowski JS; Khoury HJ; Collins RH; Blum W; Stiff P; Wirth E; Nishimoto K; DiPersio J
• Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
  Biol Blood Marrow Transplant Volume: 22 Page(s): 658 - 668
  04/01/2016 Authors: Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L
• Significant Impact of Mobilization Strategy on the Cellular Composition of Donor Allografts
  Volume: 22 Page(s): S351 - S352
  03/01/2016 Authors: Rotta M; Wei L; Kitzler R; Bradbury H; Bingman A; Vasu S; Jaglowski S; Blum W; Klisovic R; Penza S
• Antithymocyte Globulin (ATG) 4.5 Vs. 6.0 Mg/Kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)
  Volume: 22 Page(s): S316 - S317
  03/01/2016 Authors: Issa H; Ruppert AS; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos LA; Klisovic R; Vasu S; Blum W
• Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials.
  Am J Hematol Volume: 91 Page(s): 199 - 204
  02/01/2016 Authors: Castillo JJ; Mulkey F; Geyer S; Kolitz JE; Blum W; Powell BL; George SL; Larson RA; Stone RM
• Tocilizumab for steroid refractory acute graft-versus-host disease.
  Leuk Lymphoma Volume: 57 Page(s): 81 - 85
  01/01/2016 Authors: Roddy JVF; Haverkos BM; McBride A; Leininger KM; Jaglowski S; Penza S; Klisovic R; Blum W; Vasu S; Hofmeister CC
• Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
  Biol Blood Marrow Transplant Volume: 22 Page(s): 71 - 79
  01/01/2016 Authors: Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM
• Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
  J Clin Oncol Volume: 33 Page(s): 4167 - 4175
  12/10/2015 Authors: Devine SM; Owzar K; Blum W; Mulkey F; Stone RM; Hsu JW; Champlin RE; Chen Y-B; Vij R; Slack J
• Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)
  Volume: 126
  12/03/2015 Authors: Issa H; Ruppert AS; Elder P; Hofmeister C; Benson DM; Penza S; Andritsos LA; Klisovic RB; Vasu S; Blum W
• In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease
  Volume: 126
  12/03/2015 Authors: Mitchell S; Orwick S; Cannon M; Goettl VM; LaFollette TD; Baloglu E; Senapedis W; Walker AR; Bhatnagar B; Mims AS
• Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)
  Volume: 126
  12/03/2015 Authors: Sweet KL; Pemmaraju N; Lane AA; Stein AS; Vasu S; Blum W; Rizzieri DA; Wang ES; Rowinsky EK; Szarek M
• Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia.
  Leukemia Volume: 29 Page(s): 2382 - 2389
  12/01/2015 Authors: Park I-K; Mundy-Bosse B; Whitman SP; Zhang X; Warner SL; Bearss DJ; Blum W; Marcucci G; Caligiuri MA
• SL-401 activity against AML blasts correlates with CD123 levels and does not down-regulate CD123 expression
  Volume: 75
  08/01/2015 Authors: Mani R; Gopalakrishnan B; Mo X; Brooks C; Blum W; Lozanski G; Vasu S; Muthusamy N
• XPO1 INHIBITION USING SELINEXOR SYNERGIZES WITH CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA (AML) BY TARGETING DNA REPAIR GENES
  Volume: 100 Page(s): 212 - 212
  06/01/2015 Authors: Yu X; Kashyap T; Ranganathan P; Bhatnagar B; Shacham S; Kauffman M; Blum W; Landesman Y; Garzon R
• Long-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine
  Volume: 33
  05/20/2015 Authors: Khoury HJ; Collins R; Blum WG; Stiff PJ; Lebkowski J; Wirth E; Nishimoto K; DiPersio JF
• Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia.
  Volume: 33
  05/20/2015 Authors: Sanford D; Blum WG; Ravandi F; Klisovic RB; Borthakur G; Walker AR; Garcia-Manero G; Marcucci G; Wierda WG; Whitman SP
• Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
  Blood Volume: 125 Page(s): 2689 - 2692
  04/23/2015 Authors: Ranganathan P; Yu X; Santhanam R; Hofstetter J; Walker A; Walsh K; Bhatnagar B; Klisovic R; Vasu S; Phelps MA
• Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.
  Leuk Lymphoma Volume: 56 Page(s): 1058 - 1065
  04/01/2015 Authors: Salem G; Ruppert AS; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos L; Klisovic R; Vasu S; Blum W
• Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT)
  Volume: 50 Page(s): S397 - S398
  03/01/2015 Authors: Efebera YA; Geyer S; Bingman A; Elder P; Kitzler R; Coombes K; Hennelly C; Cortright K; Andritsos L; Jaglowski S
• Impact of Atorvastatin on Immune Reconstitution and cytokines of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
  Volume: 50 Page(s): S398 - S398
  03/01/2015 Authors: Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmiester CC; Benson DM
• CALGB 100801 (Alliance): A phase II multi-center study of azacitidine (AZA) following allogeneic transplantation using a "test dose'' targeted busulfan conditioning regimen for high risk myelodysplasia and older patients with acute myeloid leukemia
  Volume: 50 Page(s): S440 - S441
  03/01/2015 Authors: Vij R; Hars V; Blum W; Shore T; Rapoport A; Shea T; Hoke E; Stone R; Friedman P; Owzar K
• A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies
  Volume: 21 Page(s): S331 - S332
  02/01/2015 Authors: Haverkos B; Cortright K; Andritsos LA; Blum W; Klisovic R; Vasu S; Goldenberg DM; Wegener W; Devine SM; Jaglowski S
• Expression and prognostic impact of lncRNAs in acute myeloid leukemia.
  Proc Natl Acad Sci U S A Volume: 111 Page(s): 18679 - 18684
  12/30/2014 Authors: Garzon R; Volinia S; Papaioannou D; Nicolet D; Kohlschmidt J; Yan PS; Mrzek K; Bucci D; Carroll AJ; Baer MR
• A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies
  Volume: 124
  12/06/2014 Authors: Haverkos BM; Cortright K; Andritsos LA; Blum W; Klisovic RB; Vasu S; Goldenberg DM; Wegener WA; Devine SM; Jaglowski SM
• Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)
  Volume: 124
  12/06/2014 Authors: Efebera YA; Geyer S; Bingman A; Elder P; Kitzler R; Coombes K; Hennelly C; Cortright K; Andritsos LA; Jaglowski SM
• Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
  Volume: 124
  12/06/2014 Authors: Efebera YA; Geyer S; Bingman A; Kitzler R; Elder P; Andritsos LA; Jaglowski SM; Vasu S; Blum W; Klisovic RB
• A Phase I Dose Escalation Study of Lenalidomide Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation
  Volume: 124
  12/06/2014 Authors: Andritsos LA; Blum W; Klisovic RB; Vasu S; Penza S; Lee J; Marcucci G; Byrd JC; Devine SM
• Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation
  Volume: 124
  12/06/2014 Authors: Vasu S; Bingman A; Geyer S; Elder P; Kitzler R; Bradbury H; Odonnell L; Blum W; Jaglowski SM; Andritsos LA
• Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)
  Volume: 124
  12/06/2014 Authors: Marcucci G; Geyer S; Zhao W; Caroll AJ; Bucci D; Uy GL; Blum W; Pardee T; Wetzler M; Stock W
• CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a "test dose" Strategy to Target Busulfan Exposure
  Volume: 124
  12/06/2014 Authors: Vij R; Hars V; Blum W; Shore TB; Rapoport AP; Shea TC; Hoke E; Stone RM; Friedman P; Owzar K
• Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
  Cancer Chemother Pharmacol Volume: 74 Page(s): 927 - 938
  11/01/2014 Authors: Beumer JH; Owzar K; Lewis LD; Jiang C; Holleran JL; Christner SM; Blum W; Devine S; Kolitz JE; Linker C
• The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.
  Bone Marrow Transplant Volume: 49 Page(s): 1323 - 1329
  10/01/2014 Authors: Jaglowski SM; Ruppert AS; Hofmeister CC; Elder P; Blum W; Klisovic R; Vasu S; Penza S; Efebera YA; Benson DM
• Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
  Leuk Lymphoma Volume: 55 Page(s): 1332 - 1336
  06/01/2014 Authors: Klisovic RB; Blum W; Liu Z; Xie Z; Kefauver C; Huynh L; Zwiebel JA; Devine SM; Byrd JC; Grever MR
• Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.
  Leuk Lymphoma Volume: 55 Page(s): 1304 - 1308
  06/01/2014 Authors: Walker AR; Klisovic RB; Garzon R; Schaaf LJ; Humphries K; Devine SM; Byrd JC; Grever MR; Marcucci G; Blum W
• XPO1 INHIBITION USING SELINEXOR RESTORES TOPOISOMERASE IIA (TOPO IIA) LOCALIZATION TO THE NUCLEUS AND SENSITIZE PIMARY REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA (AML) BLASTS TO CHEMOTHERAPY
  Volume: 99 Page(s): 292 - 293
  06/01/2014 Authors: Yu X; Ranganathan P; Bhatnagar B; Hofstetter J; Shacham S; Kauffman M; Blum W; Garzon R
• SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
  J Clin Invest Volume: 124 Page(s): 1512 - 1524
  04/01/2014 Authors: Alachkar H; Santhanam R; Maharry K; Metzeler KH; Huang X; Kohlschmidt J; Mendler JH; Benito JM; Hickey C; Neviani P
• Cancer immunology, success without sequencing.
  J Natl Compr Canc Netw Volume: 12 Page(s): 443 - 445
  03/01/2014 Authors: Blum W
• Novel therapies in AML: reason for hope or just hype?
  Am Soc Clin Oncol Educ Book Page(s): e341 - e351
  01/01/2014 Authors: Larkin K; Blum W
• Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).
  Haematologica Volume: 99 Page(s): 111 - 115
  01/01/2014 Authors: Wetzler M; Watson D; Stock W; Koval G; Mulkey FA; Hoke EE; McCarty JM; Blum WG; Powell BL; Marcucci G
• Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.
  Leukemia Volume: 27 Page(s): 2379 - 2382
  12/01/2013 Authors: Bernot KM; Siebenaler RF; Whitman SP; Zorko NA; Marcucci GG; Santhanam R; Ahmed EH; Ngangana M; McConnell KK; Nemer JS
• Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease.
  Blood Volume: 122 Page(s): 3778 - 3783
  11/28/2013 Authors: Bernot KM; Nemer JS; Santhanam R; Liu S; Zorko NA; Whitman SP; Dickerson KE; Zhang M; Yang X; McConnell KK
• DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML
  Volume: 122
  11/15/2013 Authors: Roboz GJ; Issa J-P; Rizzieri D; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Feldman EJ
• Decitabine Priming Enhances The Antileukemic Effects Of The Selective Inhibitor Of Nuclear Export (SINE) CRM1/XPO1 Antagonist (Selinexor) In Acute Myeloid Leukemia (AML)
  Volume: 122
  11/15/2013 Authors: Ranganathan P; Yu X; Hofstetter J; Santhanam R; Schacham S; Kauffman M; Blum W; Marcucci G; Garzon R
• PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
  J Clin Invest Volume: 123 Page(s): 4144 - 4157
  10/01/2013 Authors: Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM
• Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
  Leuk Lymphoma Volume: 54 Page(s): 1996 - 2002
  09/01/2013 Authors: Walker AR; Klisovic R; Johnston JS; Jiang Y; Geyer S; Kefauver C; Binkley P; Byrd JC; Grever MR; Garzon R
• Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.
  Clin Cancer Res Volume: 19 Page(s): 2355 - 2367
  05/01/2013 Authors: Huang X; Schwind S; Yu B; Santhanam R; Wang H; Hoellerbauer P; Mims A; Klisovic R; Walker AR; Chan KK
• Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.
  Br J Haematol Volume: 161 Page(s): 406 - 410
  05/01/2013 Authors: Phillips CL; Davies SM; McMasters R; Absalon M; O'Brien M; Mo J; Broun R; Moscow JA; Smolarek T; Garzon R
• Targeting the miR29b/Sp1/Dnmt pathway for curative therapy in MII-PTD/Flt3-ITD acute myeloid leukemia
  Volume: 73
  04/15/2013 Authors: Bernot KM; Nemer JS; Santhanam R; Liu S; Marcucci GG; Zorko NA; Whitman SP; Yan P; Frankhouser D; Bundschuh R
• Preclinical and pharmacological activities of protein arginine methyltransferase 5(PRMT5) enzyme inhibition in acute myeloid leukemia.
  Volume: 73
  04/15/2013 Authors: Tarighat SS; Mahasenan K; Perrotti D; Garzon R; Caligiuri M; Li C; Blum W; Marcucci G; Baiocchi RA
• Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
  Leukemia Volume: 27 Page(s): 871 - 878
  04/01/2013 Authors: Mims A; Walker AR; Huang X; Sun J; Wang H; Santhanam R; Dorrance AM; Walker C; Hoellerbauer P; Tarighat SS
• Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
  J Clin Oncol Volume: 31 Page(s): 923 - 929
  03/01/2013 Authors: Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees P; Wang ES
• Emerging immunotherapies in older adults with acute myeloid leukemia.
  Curr Opin Hematol Volume: 20 Page(s): 107 - 114
  03/01/2013 Authors: Vasu S; Blum W
• Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics
  Volume: 19 Page(s): S320 - S321
  02/01/2013 Authors: Cohen JB; McBride A; Geyer S; Bingman A; Elder P; Blum W; Klisovic R; Penza S; Andritsos LA; Benson DM
• Impact of Atorvastatin On Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)
  Volume: 19 Page(s): S202 - S202
  02/01/2013 Authors: Efebera Y; Geyer S; Bingman A; Kitzler R; Elder P; Hennelly C; Andritsos LA; Jaglowski S; Blum W; Klisovic R
• LENALIDOMIDE PHARMACOKINETICS IN COMBINATION WITH IDARUBION AND CYTARABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA.
  Volume: 93 Page(s): S66 - S67
  02/01/2013 Authors: Jiang Y; Wang J; Walker A; Li X; Drake A; Schaaf L; Byrd J; Marcucci G; Grever M; Blum W
• Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis)
  Volume: 19 Page(s): S186 - S186
  02/01/2013 Authors: Pandit A; Wei L; Elder P; Falk W; Sell M; Hofmeister CC; Benson DM; Penza S; Andritsos LA; Klisovic R
• Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoeitic Stem Cell Transplant (HSCT)
  Volume: 19 Page(s): S304 - S305
  02/01/2013 Authors: Salem G; Ruppert AS; Elder P; Hofmeister CC; Benson DM; Penza S; Andritsos LA; Klisovic R; Vasu S; Blum W
• inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
  Blood Volume: 121 Page(s): 385 - 391
  01/10/2013 Authors: Schwind S; Edwards CG; Nicolet D; Mrzek K; Maharry K; Wu Y-Z; Paschka P; Eisfeld A-K; Hoellerbauer P; Becker H
• Lenalidomide-mediated enhanced translation of C/EBP-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
  Blood Volume: 121 Page(s): 159 - 169
  01/03/2013 Authors: Hickey CJ; Schwind S; Radomska HS; Dorrance AM; Santhanam R; Mishra A; Wu Y-Z; Alachkar H; Maharry K; Nicolet D
• In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.
  AAPS J Volume: 15 Page(s): 242 - 249
  01/01/2013 Authors: Wang H; Chen P; Wang J; Santhanam R; Aimiuwu J; Saradhi UVV; Liu Z; Schwind S; Mims A; Byrd JC
• Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD)
  Volume: 120
  11/16/2012 Authors: Vasu S; Jaglowski SM; Geyer S; Bingman A; Elder P; Yu J; Andritsos LA; Blum W; Klisovic RB; Penza S
• Priming of Mir-181a in Acute Myeloid Leukemia (AML) to Increase Chemosensitivity: A Phase I Trial of Lenalidomide (LEN) Followed by Idarubicin and Cytarabine
  Volume: 120
  11/16/2012 Authors: Blum W; Klisovic RB; Walker A; Schwind S; Jiang Y; Wang J; Phelps M; Geyer S; Devine SM; Walsh K
• Phase I Study of the Combination of Azacitidine (AZA) with MEC (Mitoxantrone, Etoposide and Cytarabine) Salvage Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia (AML): Early Results
  Volume: 120
  11/16/2012 Authors: Klisovic RB; Wang H; Walker A; Walsh K; Vasu S; Garzon R; Devine SM; Wang J; Garr C; Norris A
• Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
  Blood Volume: 120 Page(s): 2466 - 2474
  09/20/2012 Authors: Yan P; Frankhouser D; Murphy M; Tam H-H; Rodriguez B; Curfman J; Trimarchi M; Geyer S; Wu Y-Z; Whitman SP
• Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.
  Blood Volume: 120 Page(s): 1765 - 1773
  08/30/2012 Authors: Ranganathan P; Yu X; Na C; Santhanam R; Shacham S; Kauffman M; Walker A; Klisovic R; Blum W; Caligiuri M
• Acute lymphoblastic leukemia.
  J Natl Compr Canc Netw Volume: 10 Page(s): 858 - 914
  07/01/2012 Authors: Alvarnas JC; Brown PA; Aoun P; Ballen KK; Bellam N; Blum W; Boyer MW; Carraway HE; Coccia PF; Coutre SE
• Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.
  Blood Volume: 119 Page(s): 6025 - 6031
  06/21/2012 Authors: Blum W; Schwind S; Tarighat SS; Geyer S; Eisfeld A-K; Whitman S; Walker A; Klisovic R; Byrd JC; Santhanam R
• RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.
  Blood Volume: 119 Page(s): 5229 - 5238
  05/31/2012 Authors: Aimiuwu J; Wang H; Chen P; Xie Z; Wang J; Liu S; Klisovic R; Mims A; Blum W; Marcucci G
• Effect of age on the pharmacokinetics of busulfan (Bu): An alliance study.
  Volume: 30
  05/20/2012 Authors: Beumer JH; Lewis LD; Owzar K; Jiang C; Holleran JL; Christner SM; Blum WG; Devine SM; Kolitz JE; Linker CA
• A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.
  Volume: 30
  05/20/2012 Authors: Attar EC; Johnson JL; Amrein PC; Lozanski G; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees PM; Wang ES
• RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.
  Blood Volume: 119 Page(s): 4708 - 4718
  05/17/2012 Authors: Troeger A; Johnson AJ; Wood J; Blum WG; Andritsos LA; Byrd JC; Williams DA
• DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.
  Leukemia Volume: 26 Page(s): 1106 - 1107
  05/01/2012 Authors: Metzeler KH; Walker A; Geyer S; Garzon R; Klisovic RB; Bloomfield CD; Blum W; Marcucci G
• AR42, a histone deacetylase inhibitor (HDACI), increases microRNA (miR)-29b and sensitizes cells to decitabine (DAC) treatment: A novel epigenetic-targeting approach in acute myeloid leukemia (AML)
  Volume: 72
  04/15/2012 Authors: Mims AS; Walkers AR; Hoellerbauer P; Huang X; Chan KK; Klisovic RB; Perrotti D; Caligiuri MA; Byrd JC; Chen C-S
• Immunoglobulin reactivity analysis of chronic lymphocytic leukemia patients unveils Lymphocyte Cytosolic Protein 1 (LCP1) as a novel CLL exosome antigen
  Volume: 72
  04/15/2012 Authors: Dubovsky JA; Andritsos LA; Blum W; Johnson A; Muthusamy N; Byrd JC
• Synthetic microRNA (miR)-181a nanoparticles (NP) target RAS and sensitize cells to daunorubicin (DNR) in acute myeloid leukemia (AML)
  Volume: 72
  04/15/2012 Authors: Huang X; Sebastian S; Eisfeld A-K; Jin Y; Yu B; Hickey C; Pang J; Ramasamy S; Chan K; Perrotti D
• Methods for high-throughput MethylCap-Seq data analysis.
  BMC Genomics Volume: 13 Suppl 6 Page(s): S14
  01/01/2012 Authors: Rodriguez BAT; Frankhouser D; Murphy M; Trimarchi M; Tam H-H; Curfman J; Huang R; Chan MWY; Lai H-C; Parikh D
• Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
  Hematol Oncol Volume: 29 Page(s): 202 - 210
  12/01/2011 Authors: Hamadani M; Craig M; Phillips GS; Abraham J; Tse W; Cumpston A; Gibson L; Remick SC; Bunner P; Leadmon S
• Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute-Myeloid Leukemia (AML)
  Volume: 118 Page(s): 430 - 430
  11/18/2011 Authors: Walker AR; Metzeler KH; Geyer S; Becker H; Schwind S; Whitman SP; Curfman J; Wu Y-Z; Perrotti D; Klisovic RB
• Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16)
  Volume: 118 Page(s): 1077 - 1077
  11/18/2011 Authors: Edwards CG; Maharry K; Mrozek K; Schwind S; Paschka P; Nicolet D; Kohlschmidt J; Prior TW; Wu Y-Z; Kolitz JE
• Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)
  Volume: 118 Page(s): 39 - 39
  11/18/2011 Authors: Huang X; Schwind S; Yu B; Pang J; Santhanam R; Chan KK; Garzon R; Blum W; Bloomfield CD; Liu S
• Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures
  Volume: 118 Page(s): 1476 - 1477
  11/18/2011 Authors: Mendler JH; Maharry K; Radmacher MD; Mrozek K; Kohlschmidt J; Nicolet D; Becker H; Metzeler KH; Schwind S; Whitman SP
• TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
  J Clin Oncol Volume: 29 Page(s): 1373 - 1381
  04/01/2011 Authors: Metzeler KH; Maharry K; Radmacher MD; Mrzek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP
• Hypomethylating agents in myelodysplastic syndromes.
  Clin Adv Hematol Oncol Volume: 9 Page(s): 123 - 128
  02/01/2011 Authors: Blum WG
• MUTATIONS IN THE TET ONCOGENE FAMILY MEMBER 2 (TET2) GENE REFINE THE NEW EUROPEAN LEUKEMIA NET RISK CLASSIFICATION OF PRIMARY, CYTOGEINETICALLY NORMAL ACUTE MYELOID LEUKEMIA IN ADULTS: A CANCER AND LEUKEMIA GROUP B STUDY
  Volume: 90 Page(s): S8 - S8
  02/01/2011 Authors: Metzeler KH; Maharry K; Radmacher MD; Mrozek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP
• HIGHER BUSULFAN DOSE INTENSITY DOES NOT IMPROVE OUTCOMES OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) FOLLOWING FLUDARABINE/BUSULFAN/ATG (FBA)-BASED REDUCED TOXICITY CONDITIONING (RTC)
  Volume: 17 Page(s): S306 - S306
  02/01/2011 Authors: Hamadani M; Craig M; Abraham J; Tse W; Cumpston A; Gibson LF; Remick SC; Leadmon S; Elder P; Hofmeister C
• A Scalable, Flexible Workflow for MethylCap-Seq Data Analysis.
  Page(s): 1 - 4
  01/01/2011 Authors: Rodriguez B; Tam H-H; Frankhouser D; Trimarchi M; Murphy M; Kuo C; Parikh D; Ball B; Schwind S; Curfman J
• Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
  J Clin Oncol Volume: 28 Page(s): 4919 - 4925
  11/20/2010 Authors: Blum W; Klisovic RB; Becker H; Yang X; Rozewski DM; Phelps MA; Garzon R; Walker A; Chandler JC; Whitman SP
• Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)
  Volume: 116 Page(s): 1349 - 1349
  11/19/2010 Authors: Blum W; Klisovic RB; Garzon R; Walker A; Schwind S; Liu S; Schaaf L; Garr C; Devine SM; Greyer MR
• Challenges for Conducting Clinical Trials Evaluating Maintenance Chemotherapy In Acute Myeloid Leukemia (AML): a Cancer and Leukemia Group B (CALGB) Study
  Volume: 116 Page(s): 898 - 899
  11/19/2010 Authors: Blum W; Donohue K; Marcucci G; DeAngelo DJ; Uy GL; Powell BL; Stock W; Baer M; Kolitz JE; Wetzler M
• Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60-75 Years: Cancer and Leukemia Group B (CALGB) Study 10502
  Volume: 116 Page(s): 150 - 150
  11/19/2010 Authors: Attar EC; Donohue KA; Amrein PC; Wadleigh M; DeAngelo DJ; Kolitz JE; Powell BL; Voorhees PM; Wang ES; Blum W
• Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study
  Volume: 116 Page(s): 48 - 49
  11/19/2010 Authors: Metzeler KH; Maharry K; Radmacher MD; Mrozek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP
• Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.
  Haematologica Volume: 95 Page(s): 1098 - 1105
  07/01/2010 Authors: Blum W; Phelps MA; Klisovic RB; Rozewski DM; Ni W; Albanese KA; Rovin B; Kefauver C; Devine SM; Lucas DM
• TET2 MUTATIONS OCCUR IN OVER 20% OF ADULTS WITH DE NOVO CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA, AND THEIR PREVALENCE INCREASES WITH AGE: A CANCER AND LEUKEMIA GROUP B STUDY
  Volume: 95 Page(s): 12 - 13
  06/15/2010 Authors: Metzeler K; Maharry K; Margeson D; Curfman J; Becker H; Radmacher M; Mrozek K; Holland K; Whitman S; Wu Y
• A PHASE II STUDY OF GTI-2040, AN ANTISENSE TO RIBONUCLEOTIDE REDUCTASE IN COMBINATION WITH HIGH-DOSE CYTARABINE IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
  Volume: 95 Page(s): 27 - 27
  06/15/2010 Authors: Klisovic B; Blum W; Chen P; Xie Z; Liu S; Walker A; Devine S; Garzon R; Byrd J; Wetzler M
• A PHASE II STUDY OF GTI-2040, AN ANTISENSE TO RIBONUCLEOTIDE REDUCTASE IN COMBINATION WITH HIGH-DOSE CYTARABINE IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
  Volume: 95 Page(s): 27 - 27
  06/01/2010 Authors: Klisovic B; Blum W; Chen P; Xie Z; Liu S; Walker A; Devine S; Garzon R; Byrd J; Wetzler M
• TET2 MUTATIONS OCCUR IN OVER 20% OF ADULTS WITH DE NOVO CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA, AND THEIR PREVALENCE INCREASES WITH AGE: A CANCER AND LEUKEMIA GROUP B STUDY
  Volume: 95 Page(s): 12 - 13
  06/01/2010 Authors: Metzeler K; Maharry K; Margeson D; Curfman J; Becker H; Radmacher M; Mrozek K; Holland K; Whitman S; Wu Y
• Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
  Proc Natl Acad Sci U S A Volume: 107 Page(s): 7473 - 7478
  04/20/2010 Authors: Blum W; Garzon R; Klisovic RB; Schwind S; Walker A; Geyer S; Liu S; Havelange V; Becker H; Schaaf L
• Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
  Blood Volume: 115 Page(s): 2619 - 2629
  04/01/2010 Authors: Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA
• Evidence-based mini-review: Should patients over the age of 60 with INT-2 or high-risk myelodysplastic syndrome undergo allogeneic stem cell transplantation prior to progression to acute myelogenous leukemia?
  Hematology Am Soc Hematol Educ Program Volume: 2010 Page(s): 322 - 324
  01/01/2010 Authors: Schroeder MA; Blum W
• How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.
  Hematology Am Soc Hematol Educ Program Volume: 2010 Page(s): 314 - 321
  01/01/2010 Authors: Blum W
• Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML)
  Volume: 114 Page(s): 815 - 816
  11/20/2009 Authors: Blum W; Klisovic RB; Walker A; Garzon R; Liu S; Schaaf LJ; Humphries K; Grever MR; Devine SM; Byrd JC
• Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine
  Volume: 114 Page(s): 1454 - 1455
  11/20/2009 Authors: Chen P; Blum W; Aimiuwu J; Upadhyayula V; Liu Z; Liu S; Pang J; Walker A; Klisovic RB; Garzon R
• Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia
  Volume: 114 Page(s): 346 - 347
  11/20/2009 Authors: Chandler JC; Klisovic RB; Phelps MA; Walker A; Garzon R; Yang X; Schaaf L; Schwind S; Becker H; Liu S
• Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.
  Volume: 114 Page(s): 1339 - 1339
  11/20/2009 Authors: Maddocks K; Lapalombella R; Blum KA; Blum W; Fischer BB; Muthusamy N; Moran ME; Holtzapfel D; Byrd JC; Johnson AJ
• Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
  Biol Blood Marrow Transplant Volume: 15 Page(s): 1422 - 1430
  11/01/2009 Authors: Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R
• Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells (vol 112, pg 5180, 2008)
  BLOOD Volume: 114 Page(s): 3506 - 3506
  10/15/2009 Authors: Lapalombella R; Yu B; Triantafillou G; Liu Q; Butchar JP; Lozanski G; Ramanunni A; Smith LL; Blum W; Andritsos L
• MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
  Blood Volume: 113 Page(s): 6411 - 6418
  06/18/2009 Authors: Garzon R; Liu S; Fabbri M; Liu Z; Heaphy CEA; Callegari E; Schwind S; Pang J; Yu J; Muthusamy N
• A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels.
  Pharm Res Volume: 26 Page(s): 1504 - 1515
  06/01/2009 Authors: Chen P; Liu Z; Liu S; Xie Z; Aimiuwu J; Pang J; Klisovic R; Blum W; Grever MR; Marcucci G
• Efficacy of a novel schedule of decitabine in previously untreated AML, age 60 or older
  Volume: 27
  05/20/2009 Authors: Blum WG; Klisovic R; Liu S; Kefauver C; Grever MR; Schaaf L; Chan K; Byrd JC; Villalona-Calero M; Marcucci G
• Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.
  Biol Blood Marrow Transplant Volume: 15 Page(s): 547 - 553
  05/01/2009 Authors: Hamadani M; Benson DM; Hofmeister CC; Elder P; Blum W; Porcu P; Garzon R; Blum KA; Lin TS; Marcucci G
• EVALUATION OF RABBIT ANTITHYMOCYTE GLOBULIN (RATG) DOSE-INTENSITY IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION (ASCT) FOLLOWING REDUCED INTENSITY CONDITIONING (RIC) WITH FLUDARABINE, BUSULFAN AND RATG (FBA)
  Volume: 15 Page(s): 5 - 5
  02/01/2009 Authors: Hamadani M; Benson DM; Porcu P; Elder P; Andritsos L; Hofmeister CC; Krugh D; Garzon R; Lin T; Marcucci G
• Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
  Blood Volume: 113 Page(s): 1002 - 1005
  01/29/2009 Authors: Fehniger TA; Byrd JC; Marcucci G; Abboud CN; Kefauver C; Payton JE; Vij R; Blum W
• Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
  Blood Volume: 112 Page(s): 5180 - 5189
  12/15/2008 Authors: Lapalombella R; Yu B; Triantafillou G; Liu Q; Butchar JP; Lozanski G; Ramanunni A; Smith LL; Blum W; Andritsos L
• Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin's Lymphomas
  Volume: 112 Page(s): 1121 - 1121
  11/16/2008 Authors: Hamadani M; Blum KA; Elder P; Lin TS; Porcu P; Hofmeister CC; Blum W; Marcucci G; Benson D; Devine S
• Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL)
  Volume: 112 Page(s): 756 - 757
  11/16/2008 Authors: Andritsos L; Hamadani M; Heerema NA; Benson D; Hofmeister CC; Blum W; Flynn J; Jones JA; Elder P; Lin TS
• Natural Killer Cell Immune Reconstitution Predicts Outcomes for Patients with Chronic Lymphocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation.
  Volume: 112 Page(s): 1133 - 1134
  11/16/2008 Authors: Benson D; Andritsos L; Hamadani M; Lin T; Flynn J; Jones J; Blum W; Elder P; Lozanski G; Byrd J
• Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age >= 60) with Previously Untreated Acute Myeloid Leukemia (AML)
  Volume: 112 Page(s): 1016 - 1016
  11/16/2008 Authors: Blum W; Klisovic R; Liu S; Garzon R; Kefauver C; Liu Z; Mickle J; Devine H; Devine S; Grever MR
• Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma.
  J Chromatogr B Analyt Technol Biomed Life Sci Volume: 871 Page(s): 15 - 21
  08/01/2008 Authors: Johnston JS; Phelps MA; Blum KA; Blum W; Grever MR; Farley KL; Dalton JT
• Epigenetics in acute myeloid leukemia.
  Semin Oncol Volume: 35 Page(s): 378 - 387
  08/01/2008 Authors: Plass C; Oakes C; Blum W; Marcucci G
• Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.
  Biol Blood Marrow Transplant Volume: 14 Page(s): 783 - 789
  07/01/2008 Authors: Hamadani M; Hofmeister CC; Jansak B; Phillips G; Elder P; Blum W; Penza S; Lin TS; Klisovic R; Marcucci G
• Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
  J Clin Invest Volume: 118 Page(s): 2427 - 2437
  07/01/2008 Authors: Ramsay AG; Johnson AJ; Lee AM; Gorgn G; Le Dieu R; Blum W; Byrd JC; Gribben JG
• Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
  Clin Cancer Res Volume: 14 Page(s): 3889 - 3895
  06/15/2008 Authors: Klisovic RB; Blum W; Wei X; Liu S; Liu Z; Xie Z; Vukosavljevic T; Kefauver C; Huynh L; Pang J
• Post-remission therapy in acute myeloid leukemia: what should I do now?
  Haematologica Volume: 93 Page(s): 801 - 805
  06/01/2008 Authors: Blum W
• Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
  J Clin Oncol Volume: 26 Page(s): 2519 - 2525
  05/20/2008 Authors: Andritsos LA; Johnson AJ; Lozanski G; Blum W; Kefauver C; Awan F; Smith LL; Lapalombella R; May SE; Raymond CA
• Preliminary results of a phase I trial with dose escalated lenalidomide (L) in separate cohorts of relapsed acute leukemia (AL) or chronic lymphocytic leukemia (CLL): evidence of activity in acute myeloid leukemia (AML) and toxicity in CLL at starting dose
  Volume: 26
  05/20/2008 Authors: Blum WG; Andritsos LA; Johnson AJ; Klisovic RB; Kefauver C; Devine SM; Marcucci G; Byrd JC
• A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.
  Clin Cancer Res Volume: 14 Page(s): 2444 - 2449
  04/15/2008 Authors: Klisovic RB; Stock W; Cataland S; Klisovic MI; Liu S; Blum W; Green M; Odenike O; Godley L; Burgt JV
• New approaches in acute myeloid leukemia.
  Best Pract Res Clin Haematol Volume: 21 Page(s): 29 - 41
  03/01/2008 Authors: Blum W; Marcucci G
• Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.
  Blood Volume: 111 Page(s): 2364 - 2373
  02/15/2008 Authors: Liu S; Liu Z; Xie Z; Pang J; Yu J; Lehmann E; Huynh L; Vukosavljevic T; Takeki M; Klisovic RB
• Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease.
  Transpl Infect Dis Volume: 10 Page(s): 24 - 26
  02/01/2008 Authors: Hamadani M; Benson DM; Blum W; Garzon R; Devine SM
• PHASE-II STUDY OF INFLIXIMAB FOR THE PROPHYLAXIS OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT)
  Volume: 14 Page(s): 130 - 131
  02/01/2008 Authors: Hamadani M; Phillips G; Elder P; Yansak B; Blum W; Penza S; Lin TS; Farag SS; Devine SM
• Final results of a dose escalation study of flavopiridol in acute leukemias using a novel-treatment schedule
  Volume: 110 Page(s): 272A - 272A
  11/16/2007 Authors: Blum W; Klisovic RB; Johnson A; Kefauver C; Phelps M; Lucas D; Huynh L; Liu S; Dalton JT; Grever MR
• High rates of early donor chimerism and low risk of chronic GVHD can be achieved in poor risk patients undergoing unrelated donor stem cell transplantation using a reduced intensity conditioning regimen incorporating fludarabine, busulfan, and rabbit ATG
  Volume: 110 Page(s): 351B - 351B
  11/16/2007 Authors: Hamadani M; Elder P; Awan F; Krugh D; Blum W; Lin T; Andritsos L; Bechtel T; Blum K; Klisovic R
• Autologous stem cell transplantation (SCT) following sequential chemotherapy and imatinib for adults with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) - CALGB study 10001
  Volume: 110 Page(s): 843A - 844A
  11/16/2007 Authors: Wetzler M; Stock W; Donohue KA; Owzar K; Sher DA; Hoke EE; McCarty JM; Blum WG; Powell BL; Bloomfield CD
• MicroRNA (miRNA)-29b targets DNMT3A and B and induces re-expression of the hypermethylated ESR1 and p15 genes in acute myeloid leukemia (AML).
  Volume: 110 Page(s): 220A - 220A
  11/16/2007 Authors: Garzon R; Liu S; Fabbri M; Liu Z; Pang J; Muthusamy N; Blum W; Chan K; Byrd JC; Croce CM
• Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
  J Clin Oncol Volume: 25 Page(s): 3884 - 3891
  09/01/2007 Authors: Blum W; Klisovic RB; Hackanson B; Liu Z; Liu S; Devine H; Vukosavljevic T; Huynh L; Lozanski G; Kefauver C
• High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma.
  Leuk Res Volume: 31 Page(s): 1069 - 1075
  08/01/2007 Authors: Benson DM; Elder PJ; Lin TS; Blum W; Penza S; Avalos B; Copelan E; Farag SS
• Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.
  Cancer Volume: 110 Page(s): 96 - 102
  07/01/2007 Authors: Ali NA; O'Brien JM; Blum W; Byrd JC; Klisovic RB; Marcucci G; Phillips G; Marsh CB; Lemeshow S; Grever MR
• Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
  J Pharmacol Exp Ther Volume: 321 Page(s): 953 - 960
  06/01/2007 Authors: Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W
• Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome.
  Semin Thromb Hemost Volume: 33 Page(s): 350 - 354
  06/01/2007 Authors: Blum W; Porcu P
• Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS.
  J Chromatogr B Analyt Technol Biomed Life Sci Volume: 850 Page(s): 206 - 212
  05/01/2007 Authors: Cheng H; Liu Z; Blum W; Byrd JC; Klisovic R; Grever MR; Marcucci G; Chan KK
• Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.
  Bone Marrow Transplant Volume: 39 Page(s): 425 - 429
  04/01/2007 Authors: Trifilio SM; Bennett CL; Yarnold PR; McKoy JM; Parada J; Mehta J; Chamilos G; Palella F; Kennedy L; Mullane K
• Hypomethylation therapy in acute myeloid leukemia
  Volume: 25 Page(s): 33 - 35
  01/01/2007 Authors: Blum W; Marcucci G
• Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
  Nucleic Acids Res Volume: 35 Page(s): e31
  01/01/2007 Authors: Liu Z; Liu S; Xie Z; Blum W; Perrotti D; Paschka P; Klisovic R; Byrd J; Chan KK; Marcucci G
• Updated results of a phase I study of flavopiridol in acute leukemias using a novel, pharmacolkinetically derived schedule: Clinical activity including hyperacute tumor lysis syndrome (TLS), pharmacokinetics (PIC), and pharmacodynamics (PD).
  Volume: 108 Page(s): 224B - 224B
  11/16/2006 Authors: Blum W; Klisovic RB; Kefauver C; Johnson A; Phelps M; Dalton JT; Lucas D; Huynh LN; Liu S; Grever MR
• Characterization of HDACI OSU42 as a novel histone deacetylase inhibitor in AML cell lines.
  Volume: 108 Page(s): 563A - 563A
  11/16/2006 Authors: Sun J; Liu S; Yu J; Wei M; Mao C; Ding H; Kearney J; Huynh L; Paschka P; Wang D
• Bortezomib-induced down-regulation of KIT is mediated by inhibition of Sp1 and NF-kB in AML1/ETO-positive cells.
  Volume: 108 Page(s): 132B - 132B
  11/16/2006 Authors: Liu S; Pang J; Yu J; Liu Z; Huynh L; Kearney J; Paschka P; Klisovic RB; Baiocchi R; Blum W
• Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.
  Volume: 108 Page(s): 476B - 476B
  11/16/2006 Authors: Ali NA; O'Brien JM; Blum W; Klisovic RB; Marcucci G; Phillips G; Marsh CB; Lemeshow S; Byrd JC; Grever MR
• Transplantation without hemolysis in a kell antigen positive patient undergoing peripheral hematopoietic stem cell transplant from a donor with anti-kell antibodies.
  Volume: 108 Page(s): 114B - 114B
  11/16/2006 Authors: Crawford RD; Krugh D; Blum W; Devine S
• Imatinib mesylate-induced complete cytogenetic response in acute myeloid leukemia with t(5;12)(q33;p13).
  Volume: 108 Page(s): 181B - 181B
  11/16/2006 Authors: Blum W; Marcucci G; Devine H; Klisovic R
• Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
  Biol Blood Marrow Transplant Volume: 12 Page(s): 749 - 757
  07/01/2006 Authors: Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin H-S; DiPersio JF; Adkins DR
• Phase I study of a novel, pharmacokinetically derived schedule of flavopiridol in acute leukemias: Clinical efficacy including hyperacute tumor lysis, pharmacokinetics, and pharmacodynamics.
  Volume: 24 Page(s): 353S - 353S
  06/20/2006 Authors: Blum W; Klisovic RB; Kefauver C; Johnson A; Phelps M; Dalton JT; Lucas D; Colevas AD; Grever MR; Marcucci G
• A phase I study of GTI-2040 (G), an antisense to ribonucleotide reductase (RNR), in combination with high-dose AraC (HiDAC) in acute myeloid leukemia (AML).
  Volume: 24 Page(s): 352S - 352S
  06/20/2006 Authors: Marcucci G; Klisovic RB; Wei W; Liu S; Paschka P; Huynh L; Zwiebel JA; Byrd JC; Grever MR; Chan K
• Updated results of a phase I study of low dose decitabine and valproic acid (VA) in patients with acute myeloid leukemia (AML): Gene reexpression, demethylation, and clinical response.
  Volume: 24 Page(s): 340S - 340S
  06/20/2006 Authors: Klisovic RB; Blum W; Hackanson B; Kefauver C; Liu S; Liu Z; Chan KK; Plass C; Grever MR; Byrd JC
• A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices.
  Pharm Res Volume: 23 Page(s): 1251 - 1264
  06/01/2006 Authors: Wei X; Dai G; Marcucci G; Liu Z; Hoyt D; Blum W; Chan KK
• Multiple sclerosis and mitoxantrone treatment-related leukemia: A single center experience
  Volume: 66 Page(s): A31 - A31
  03/14/2006 Authors: Lynn DJ; Blum W; Cataland S; Rammohan KW
• Risk factors associated with mortality among persons with breakthrough zygomycosis and prior voriconazole exposure
  Volume: 12 Page(s): 170 - 171
  02/01/2006 Authors: Trifilio SM; Bennett CL; Yarnold PR; Mebta J; Palella F; Kennedy L; Parada J; Blum W; Kontoyiannis DI
• High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
  Biol Blood Marrow Transplant Volume: 12 Page(s): 61 - 67
  01/01/2006 Authors: Blum W; Bolwell BJ; Phillips G; Farag SS; Lin TS; Avalos BR; Penza SL; Marcucci G; Byrd JC; Kalaycio ME
• Successful management of sudden, massive immune hemolysis following ABO-incompatible allogeneic PBSCT despite methotrexate GvHD prophylaxis.
  Bone Marrow Transplant Volume: 36 Page(s): 1111 - 1112
  12/01/2005 Authors: Benson DM; O'Donnell L; Krugh D; Grady T; Blum W; Williams JD; Kennedy MS; Marcucci G
• A phase I study of GTI-2040, an antisense to ribonucleotide reductase (RNR) in combination with high-dose cytarabine (HiDAC) in relapsed or refractory acute myeloid leukemia (AML): Pharmacokinetics (PK), pharmacodynamic (PD) and clinical results
  Volume: 106 Page(s): 782A - 783A
  11/16/2005 Authors: Klisovic RB; Blum W; Wei X; Liu S; Kefauver C; Huynh L; Zwiebel JA; Byrd JC; Grever MR; Marcucci G
• Phase I study of low dose decitabine in patients with acute myeloid leukemia (AML): Pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity.
  Volume: 106 Page(s): 529A - 529A
  11/16/2005 Authors: Blum W; Bruner-Klisovic R; Liu SJ; Byrd JC; Liu ZF; Chan KK; Kefauver C; Huynh L; Grever MR; Marcucci G
• Targeting epigenetic changes in acute myeloid leukemia.
  Clin Adv Hematol Oncol Volume: 3 Page(s): 855 - 882
  11/01/2005 Authors: Blum W; Marcucci G
• Comparison of de novo vs. therapy-related acute leukemia (AL) and myelodysplastic syndromes (MDS) in adults with balanced chromosome aberrations of 11q23.
  Volume: 23 Page(s): 572S - 572S
  06/01/2005 Authors: Blum W; Mrozek K; Maharry K; Raimondi SC; Carroll AJ; Larson RA; Rowley JD; Bloomfield CD
• Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
  J Clin Oncol Volume: 23 Page(s): 3404 - 3411
  05/20/2005 Authors: Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M
• Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide.
  Blood Volume: 105 Page(s): 3035 - 3041
  04/15/2005 Authors: Girgis M; Hallemeier C; Blum W; Brown R; Lin H-S; Khoury H; Goodnough LT; Vij R; Devine S; Wehde M
• High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
  Bone Marrow Transplant Volume: 35 Page(s): 653 - 661
  04/01/2005 Authors: Farag SS; Bolwell BJ; Elder PJ; Kalaycio M; Lin T; Pohlman B; Penza S; Marcucci G; Blum W; Sobecks R
• Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): Results from cancer and leukemia group B study 8461 and review of the literature - Reply
  CANCER Volume: 103 Page(s): 1316 - 1317
  03/15/2005 Authors: Blum W; Mrozek K; Bloomfield CD
• Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.
  Cancer Volume: 103 Page(s): 1316
  03/15/2005 Authors: Jourdan E; Dastugue N
• Intracellular levels of oblimersen sodium and target downregulation correlates to clinical activity of bcl-2 antisense in acute myeoid leukemia (AML).
  Volume: 104 Page(s): 331A - 331A
  11/16/2004 Authors: Marcucci G; Stock W; Dai G; Liu S; Klisovic R; Klisovic MI; Sher D; Huynh L; Frankel S; Blum W
• Association between regimen related toxicity and acute-graft-versus-host disease.
  Volume: 104 Page(s): 337B - 337B
  11/16/2004 Authors: Copelan EA; Penza S; Lin T; Blum W; Farag S; Elder P; Avalos B
• Single institution experience with two high-dose chemotherapy (HDC) conditioning regimens prior to autologous stem cell transplant (ASCT) for multiple myeloma (MM)
  Volume: 104 Page(s): 388B - 389B
  11/16/2004 Authors: Benson DM; Elder PJ; Lin T; Blum W; Penza S; Avalos B; Byrd JC; Copelan E; Farag SS
• Incidence of extramedullary relapse of acute myeloid leukemia following transplantation with busulfan-based conditioning regimens.
  Volume: 104 Page(s): 364B - 364B
  11/16/2004 Authors: Blum W; Penza S; Farag S; Avalos B; Marcucci G; Lin T; Byrd JC; Elder P; Copelan EA
• Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
  J Clin Oncol Volume: 22 Page(s): 4561 - 4566
  11/15/2004 Authors: Hoerr AL; Gao F; Hidalgo J; Tiwari D; Blum KA; Mathews V; Adkins DR; Blum W; Devine S; Vij R
• Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes.
  Bone Marrow Transplant Volume: 34 Page(s): 615 - 619
  10/01/2004 Authors: Hidalgo JD; Krone R; Rich MW; Blum K; Adkins D; Fan M-Y; Brown R; Devine S; Graubert T; Blum W
• Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature.
  Cancer Volume: 101 Page(s): 1420 - 1427
  09/15/2004 Authors: Blum W; Mrzek K; Ruppert AS; Carroll AJ; Rao KW; Pettenati MJ; Anastasi J; Larson RA; Bloomfield CD
• Early allogeneic transplantation for adults with de novo acute myeloid leukemia presenting with t(6;11)(q27;q23): Results from CALGB 8461.
  Volume: 22 Page(s): 568S - 568S
  07/15/2004 Authors: Blum W; Mrozek K; Ruppert AS; Carroll AJ; Rao KW; Pettenati MJ; Vardiman JW; Larson RA; Bloomfield CD
• Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants.
  Biol Blood Marrow Transplant Volume: 10 Page(s): 310 - 319
  05/01/2004 Authors: Hallemeier C; Girgis M; Blum W; Brown R; Khoury H; Goodnough LT; Vij R; Devine S; Wehde M; Postma S
• Allogeneic stem cell transplantation for 45 patients with myelodysplastic syndrome conditioned with an intermediate-intensity regimen of single exposure 550 cGy total body irradiation and cyclophosphamide.
  Volume: 102 Page(s): 467A - 467A
  11/16/2003 Authors: Hallemeier C; Girgis M; Khoury H; Devine S; Blum W; Vij R; Lin HS; DiPersio J; Adkins D
• Similar outcomes in patients >= 50 years old and patients < 50 years old undergoing unrelated donor bone marrow transplantation following reduced intensity conditioning with single exposure (550 cGy) total body irradiation and cyclophosphamide.
  Volume: 102 Page(s): 484A - 484A
  11/16/2003 Authors: Hallemeier C; Girgis M; Khoury H; Devine S; Blum W; Vij R; Lin HS; DiPersio J; Adkins D
• Matched unrelated transplantation in older individuals.
  Volume: 102 Page(s): 480B - 480B
  11/16/2003 Authors: Copelan E; Penza S; Lin T; Farag S; Blum W; Elder P; Ezzone S; Avalos B
• Only those refractory AML patients with low disease burden can achieve prolonged leukemia-free survival with conventional unrelated donor transplantation.
  Volume: 102 Page(s): 488A - 488A
  11/16/2003 Authors: Blum WG; Bolwell BJ; Farag SS; Lin TS; Avalos BR; Penza SL; Marcucci G; Byrd JC; Kalaycio ME; Sobecks RM
• Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity.
  Br J Haematol Volume: 123 Page(s): 110 - 113
  10/01/2003 Authors: Chohan R; Vij R; Adkins D; Blum W; Brown R; Tomasson M; Devine S; Graubert T; Goodnough LT; DiPersio JF
• Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation.
  Bone Marrow Transplant Volume: 32 Page(s): 703 - 707
  10/01/2003 Authors: Vij R; Khoury H; Brown R; Goodnough LT; Devine SM; Blum W; Adkins D; DiPersio JF
• Response: Granulocyte transfusions and cytomegalovirus infection
  BLOOD Volume: 101 Page(s): 5092 - 5092
  06/15/2003 Authors: Vij R; DiPersio J; Khoury H; Goodnough LT; Devine SM; Blum W; Adkins D
• Donor serostatus and CMV infection and disease among recipients of prophylactic granulocyte transfusions.
  Blood Volume: 101 Page(s): 5091 - 5092
  06/15/2003 Authors: Nichols WG; Price T; Boeckh M
• Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study.
  Biol Blood Marrow Transplant Volume: 9 Page(s): 397 - 404
  06/01/2003 Authors: Blum W; Khoury H; Lin H-S; Vij R; Goodnough LT; Devine S; Dipersio J; Adkins D
• Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation.
  Blood Volume: 101 Page(s): 2067 - 2069
  03/01/2003 Authors: Vij R; DiPersio JF; Venkatraman P; Trinkaus K; Goodnough LT; Brown RA; Khoury HJ; Devine SM; Oza A; Shenoy S
• Recent advances in allogeneic hematopoietic stem-cell transplantation.
  J Lab Clin Med Volume: 141 Page(s): 7 - 32
  01/01/2003 Authors: Devine SM; Adkins DR; Khoury H; Brown RA; Vij R; Blum W; DiPersio JF
• Impact of GM-CSF mobilization on the composition of donor allografts and the risk of acute GVHD following HLA-matched hematopoietic cell transplantation.
  Volume: 100 Page(s): 175A - 175A
  11/16/2002 Authors: Devine SM; Adkins DR; Khoury H; Vij R; Goodnough LT; Graubert T; Tomasson M; Blum W; DiPersio JF; Brown RA
• Low-dose (550 cGy), single-exposure total body irradiation (TBI) and cyclophosphamide as conditioning for unrelated donor (URD) bone marrow transplantation (BMT) for patients with acute myelogenous leukemia (AML) in complete remission (CR) results in reduced non-relapse mortality (NRM) and improved survival in comparison to standard TBI regimens.
  Volume: 100 Page(s): 636A - 637A
  11/16/2002 Authors: Hallemeier C; Girgis M; Blum W; Brown R; Lin HS; Khoury H; Goodnough LT; Vij R; Devine S; Wehde M
• Outcomes for patients with non-Hodgkin's lymphoma following donor transplantation using low dose, single exposure total body irradiation and cyclophosphamide conditioning: A single institution experience.
  Volume: 100 Page(s): 427A - 427A
  11/16/2002 Authors: Blum W; Girgis M; Hallemeier C; Vij R; Lin HS; Khoury H; Goodnough LT; Devine S; DiPersio J; Brown R
• Low-dose (556 cGy), single-exposure total body irradiation (TBI) with cyclophosphamide as conditioning for 99 patients undergoing unrelated donor (URD) bone marrow transplantation (BMT) results in a graft failure rate (7.1%) comparable to that observed with standard TBI-based regimens.
  Volume: 100 Page(s): 619A - 620A
  11/16/2002 Authors: Girgis M; Hallemeier C; Blum W; Brown R; Lin HS; Khoury H; Goodnough LT; Vij R; Devine S; Wehde M
• Mobilization of donors with GM-CSF plus G-CSF or GM-CSF alone results in significantly different graft composition compared to G-CSF alone.
  Volume: 100 Page(s): 825A - 825A
  11/16/2002 Authors: Devine SM; Adkins DR; Khoury H; Vij R; Goodnough LT; Graubert T; Tomasson M; Blum W; DiPersio JF; Brown RA
• Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity.
  Biol Blood Marrow Transplant Volume: 8 Page(s): 608 - 618
  01/01/2002 Authors: Blum W; Brown R; Lin HS; Zehnbauer B; Khoury H; Goodnough LT; Westervelt P; Vij R; DiPersio J; Adkins D
• Improved survival in allogeneic peripheral blood stem cell (PBSC) transplant patients who received prophylactic granulocyte transfusions from HLA-matched donors: Long-term follow-up.
  BLOOD Volume: 98 Page(s): 58A - 58A
  11/16/2001 Authors: Blum W; Hallem C; Vij R; Shenoy S; Goodnough L; Brown R; Khoury H; Westervelt P; DiPersio J; Adkins D
• Mobilization of allogeneic PBSC with GM-CSF instead of G-CSF is associated with a reduced risk of acute graft-vs-host disease (GVHD).
  BLOOD Volume: 98 Page(s): 737A - 737A
  11/16/2001 Authors: Brown RA; Adkins DR; Khoury H; Westervelt P; Goodnough L; Vij R; Blum W; DiPersio JF
• Hydroxychloroquine for prevention of acute GVHD in unrelated donor (URD) transplantation: Effect on chronic GVHD and long-term survival.
  BLOOD Volume: 98 Page(s): 368B - 368B
  11/16/2001 Authors: Khoury H; Adkins D; Pence H; Shenoy S; Blum W; Westervelt P; Vij R; Brown R; Goodnough L; DiPersio J
• Primary amyloidosis (AL) patients with significant organ dysfunction treated with conventional chemotherapy followed by single-dose total body irradiation (TBI) and autologous peripheral blood stem cell transplant (PBSC) the, IFN-alpha maintenance: Tolerance and efficacy.
  BLOOD Volume: 98 Page(s): 684A - 684A
  11/16/2001 Authors: Blum W; Brown RA; Khoury H; Lin HS; Vij R; Oza Y; Schultz P; Rearden T; Willis R; Naughton M
• Low-dose (550 cGy), single exposure total body irradiation (TBI) and cyclophosphamide as conditioning for unrelated donor (URD) bone marrow transplant (BMT) results in consistent donor cell engraftment without fatal regimen-related toxicity (RROT).
  BLOOD Volume: 98 Page(s): 478A - 479A
  11/16/2001 Authors: Girgis M; Brown RA; Khoury H; Hallemeier C; Zehnbauer B; Goodnough LT; Westervelt P; Vij R; Blum W; Lin HS
• Outcomes of stem cell transplant recipients requiring mechanical ventilation and cared for in the bone marrow transplant unit.
  BLOOD Volume: 98 Page(s): 350B - 350B
  11/16/2001 Authors: Omotoso O; Khoury H; Adkins D; Blum W; Iregui M; Westervelt P; Vij R; Brown R; Goodnough L; DiPersio J
• Low-dose (550 cGy), single exposure total body irradiation (TBI) and cyclophosphamide as conditioning for unrelated donor (URD) bone marrow transplantation (BMT) results in reduced non-relapse mortality (NRM) in comparison to standard TBI-based regimens.
  BLOOD Volume: 98 Page(s): 671A - 671A
  11/16/2001 Authors: Girgis M; Hallemeier C; Brown R; Khoury H; Zehnbauer B; Goodnough L; Westervelt P; Vij R; Blum W; Lin HS
• Sustained improvement in post transplant NK cell function following donor derived G-CSF mobilized granulocyte transfusion in recipients of allogeneic peripheral blood stem cell transplants (SCT): Can this impact survival?
  BLOOD Volume: 98 Page(s): 59A - 59A
  11/16/2001 Authors: Shenoy S; Hayashi R; Goodnough L; Khoury H; Brown R; Vij R; Blum W; DiPersio J; Adkins D